{
    "root": "303edb48-ee58-2977-e063-6294a90a5071",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "QUETIAPINE FUMARATE",
    "value": "20250313",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "Quetiapine Extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic, or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3)",
    "contraindications": "Swallow tablets whole and do not split, chew or crush (2.1) Take without food or with a light meal (approx. 300 calories) (2.1) Administer once daily, preferably in the evening (2.1) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia- Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Schizophrenia-Adolescents (13 to 17 years )(2.2) 50 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy -Children and Adolescents (10 to 17 years) (2.2) 50 mg/day 400 to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes-Adults (2.2) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants-Adults (2.2) 50 mg/day 150 to 300 mg/day 300 mg/day",
    "warningsAndPrecautions": "Quetiapine Extended-release tablets, USP 150 mg white colored, round shaped, biconvex film coated tablets, debossed with 'I1' on one side and plain on other is supplied in bottles of 60 tablets with child-resistant closure (NDC 68001-512-06).        \n       \n                     Quetiapine Extended-release tablets, USP 200 mg yellow colored, round shaped, biconvex, film coated tablets, debossed with “I2” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 68001-513-06).        \n       \n                     Quetiapine Extended-release tablets, USP 300 mg light yellow colored, round shaped, biconvex, film coated tablets, debossed with “I3” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 68001-514-06).        \n       \n                     Quetiapine Extended-release tablets, USP 400 mg white colored, round shaped, biconvex, beveled edge film coated tablets, debossed with “I4” on one side and plain on the other is supplied in bottles of 60 tablets with child-resistant closure (NDC 68001-515-06).        \n       \n                  \n                  Store quetiapine extended-release tablets, USP at 20ºC to 25ºC (68 ºF to 77 ºF). [See USP Controlled Room Temperature].",
    "adverseReactions": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation.  Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets."
}